Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Aoife Brennan BCh MMSc
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 28
- Beta
- 0.07
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 73.75
Financials
Net Income
$-13.50MEBITDA
$-15.33MFree Cash Flow
$-10.81MEPS (diluted)
$-0.18Shares Outstanding (diluted)
76.15M+553.0%Operating Expenses
$15.36MCash & Debt
$183.12MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-59.85M | $-0.88 |
| 2024 | $0.00 | $-73.90M | $-1.53 |
| 2023 | $0.00 | $-35.12M | $-1.30 |
| 2022 | $0.00 | $-45.24M | $-1.72 |
| 2021 | $0.00 | $-47.48M | $-4.24 |
| 2020 | $0.00 | $-20.67M | $-1.97 |
| 2019 | $0.00 | $-6.55M | $-0.56 |
Valuation
CLYMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsglobenewswire.com·6h ago·Neutral
Climb Bio to Present at Upcoming Investor Conferences WELLESLEY HILLS, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below.
View source ↗
Earnings
Thu, Nov 5(in 2 months)
Consensus estimate $-0.21 per share
Typical surprise +13.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.18 vs $-0.21beat
- Thu, May 7$-0.20 vs $-0.26beat
- Thu, Mar 5$-0.26 vs $-0.20miss
- Thu, Nov 6$-0.19 vs $-0.16miss
- Tue, Aug 12$-0.13 vs $-0.19beat
- Wed, May 14$-0.31 vs $-0.15miss
Estimates and results for CLYM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CLYM officers and directors.
- Bought
- $780k
- Sold
- $1.3m
3 trades
9 trades
- Brennan Aoifesold
- Thomas Stephen Basilsold
- Thomas Stephen Basilsold
- Thomas Stephen Basilsold
- Thomas Stephen Basilsold
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
57 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.